Valsar

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Valsar

Quick Facts

Property Description
Active ingredient Valsartan
Form Oral tablet, capsule, or suspension
Pharmacological class Angiotensin II Receptor Blocker (ARB)
General purpose Reducing strain on the heart; normalizing blood pressure
Origin Synthetic nonpeptide derivative

What Type of Medicine is Valsar (Valsartan)?

Valsar is a synthetic, prescription-only medication whose active component, Valsartan, is classified as an Angiotensin II Receptor Blocker (ARB). This class of medication functions as an Angiotensin II Receptor Antagonist, positioning Valsar among the core agents used to manage high blood pressure and other conditions affecting heart function. Valsartan is a synthetic, nonpeptide compound derived from L-valine, giving it a specific chemical identity as a monocarboxylic acid amide within a biphenylyltetrazole structure. This class of medication is used to achieve sustained arterial pressure control.


Composition and Available Forms of Valsar

The medication is defined by its active component, Valsartan, and is predominantly available in preparations designed for oral administration. As a single-entity product (monotherapy), Valsar contains the active substance Valsartan along with standard oral excipients. It is available in common forms such as the oral tablet and oral capsule, with an oral suspension (liquid form) also available to support various patient needs, including children aged one year and older. While available alone, Valsartan is also utilized in fixed-dose combination products with complementary pharmacological agents, a structural approach designed to offer comprehensive circulatory support.


How Does Valsar Generally Support the Heart and Circulation?

Valsar's core function is to support cardiovascular health by promoting vessel relaxation and reducing the resistance the heart faces when pumping blood. It achieves this by performing a targeted RAAS blockade (Renin-Angiotensin-Aldosterone System). The Valsartan molecule selectively binds to and blocks the Angiotensin II Type 1 (AT1) receptors, effectively preventing the hormone Angiotensin II from exerting its tightening effect on blood vessels. This blockade promotes vasodilation (blood vessel relaxation), which lessens the pressure, or afterload, on the heart. This action is intended to provide a cardioprotective effect, helping the heart work more efficiently and smoothly by reducing overall strain.

Regulatory References

  1. Physiology, Renin Angiotensin System - NCBI Bookshelf
  2. Cardiac Afterload - CV Physiology

What side effects are possible with Valsar?

Possible Side Effects and Safety Information

The safety profile of Valsar (Valsartan) is formally documented in government regulatory sources, which classify possible adverse reactions by frequency and the body system affected. These classifications establish the risk profile without providing clinical advice.


Frequency and System-Organ Classes

The adverse reactions are grouped into categories based on official reporting frequency (Very Common, Common, Uncommon, etc.).

Classification Common Examples (Reported Frequently)
Common Dizziness, Fatigue, Hypotension, Diarrhea.
Uncommon Vertigo, Cough, Abdominal pain, Syncope (fainting).

The official labeling organizes effects into System-Organ Classes (SOCs), including Nervous system disorders (e.g., dizziness), Vascular disorders, Gastrointestinal disorders, and Renal and urinary disorders.


Serious Adverse Reactions and Restrictions

Certain reactions are highlighted in regulatory texts due to their clinical significance. Serious adverse reactions documented include Angioedema (swelling of the face, lips, tongue, or throat) and sudden deterioration of kidney function, known as Acute Renal Failure.

Specific constraints regarding use are also defined in the official prescribing information:

  • Pregnancy Contraindication: Valsar is contraindicated during the second and third trimesters of pregnancy due to the documented risk of fetal injury and death.
  • Existing Conditions: Caution is officially noted regarding use in patients with a history of Angioedema related to previous ACE inhibitor or ARB treatment, and those with severe hepatic impairment.
  • Time-Related Pattern: The risk of Hypotension is explicitly noted as being particularly relevant during the initial phase of treatment, especially in patients who are volume-depleted.

Overdose and Emergency Response

Overdose and When to Seek Help

The information in this section is based strictly on official documentation from government regulatory sources, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).


Documented Overdose Manifestations

The most commonly expected sign of an overdose with Valsar (Valsartan) is profound hypotension (severely low blood pressure). This can lead to associated symptoms such as dizziness and, in severe cases, syncope (loss of consciousness).

Severe hypotension also carries the risk of serious outcomes, including circulatory shock and secondary acute renal impairment.


Official Emergency Actions Required

If an overdose is suspected, immediate medical attention is required; contact emergency services or a poison control center right away.

Management is primarily symptomatic and supportive, focusing on stabilizing blood pressure. If excessive hypotension occurs, regulatory guidance states the patient should be placed in the supine position (lying on the back). If positioning is insufficient, an intravenous infusion of normal saline may be administered.

No specific antidote exists for Valsartan overdose. Furthermore, the drug is not effectively removed by hemodialysis due to its high level of plasma protein binding.

Therapeutic Uses of Valsar

What Valsar Treats: Main Uses and Benefits

Valsar is generally applied across domains where additional symptomatic support is needed for conditions linked to cardiovascular strain. The core therapeutic utility is applied across these domains where supportive symptomatic management is considered relevant. The medication is used for conditions presenting with systemic or localized discomfort, including hypertension and heart failure.


Controlling Chronic High Blood Pressure (Hypertension)

Valsar is commonly used to help with sustained systemic hypertension, a condition presenting with symptoms related to heightened physiological activity (chronic, excessive pressure). This therapeutic approach may assist with managing symptoms linked to organ-specific functional stress caused by chronic hypertension. This supportive benefit helps maintain a sense of stability when symptoms are more noticeable.


Supporting Heart Function and Heart Failure

The medication is relevant in conditions characterized by periods of heightened symptoms linked to heart function. It is applied across domains where additional symptomatic support is needed to address impaired Left Ventricular Dysfunction and Heart Failure. It is relevant for managing symptoms that create noticeable physiological strain on the heart, which helps ease the overall symptom burden of the condition.


Quick Fact: Relief for Sustained Pressure
Valsar assists in managing symptoms of chronic, excessive arterial pressure, and may contribute to improved comfort during periods of heightened symptoms.

Regulatory References

  1. NIH DailyMed official label for Valsartan

Eligibility and Restrictions for Use

Valsar (valsartan) is an angiotensin II receptor blocker (ARB) whose eligibility for use is strictly defined by regulatory health authorities based on patient population and specific health conditions. Contraindications are absolute exclusions from treatment:

  • Pregnancy: The medicine is strictly contraindicated during the second and third trimesters of pregnancy due to the risk of injury and death to the developing fetus; it must be discontinued as soon as possible if pregnancy is detected.
  • Hypersensitivity: It is contraindicated in patients with a known history of an allergic reaction or angioedema related to valsartan or any other ARB.
  • Concomitant Therapy: Use is contraindicated alongside aliskiren in patients who have diabetes or moderate to severe renal impairment (e.g., glomerular filtration rate, GFR, <60 mL/min/1.73 m^2 ).

Eligibility and Restricted Use

For Age-Related Use, the medicine is approved for adults and for pediatric patients 6 years of age and older to treat high blood pressure, but use is not recommended in children under 6 years. For Lactation, breastfeeding is generally not recommended.

Patients with certain conditions, such as severe hepatic impairment or biliary cirrhosis, are generally excluded or require careful consideration before use.

What should I know about interactions with other medicines?

Valsar's (Valsartan) interaction profile is defined by pharmacodynamic reinforcement and specific pharmacokinetic changes, as described in official regulatory documents.

Category Official Regulatory Documentation
Medicinal product categories with documented interactions Other Renin-Angiotensin System (RAS) inhibitors, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), agents that increase serum potassium, and Lithium salts.
Specific interacting medicines (if explicitly listed) Aliskiren, Potassium-sparing diuretics (e.g., Spironolactone), Potassium supplements, and Potassium-containing salt substitutes.
Mechanistic basis of interactions Pharmacodynamic reinforcement (dual blockade of the RAS, additive effects on potassium levels); Transporter inhibition (potential increase in Valsartan exposure via OATP1B1/OATP1B3 and MRP2 inhibitors).

Official Interaction Statements

  • Co-administration with Aliskiren is contraindicated in specific patient populations, including those with diabetes mellitus or those with moderate-to-severe renal impairment (GFR less than 60 mL/ min/1.73 m^2).
  • The combination with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may lead to an attenuation of the antihypertensive effect and an increased risk of worsening renal function.
  • The use of Potassium-sparing diuretics, potassium supplements, or potassium-containing salt substitutes may formally increase the documented risk of hyperkalemia (elevated serum potassium levels).
  • Concomitant use with Lithium may result in a reversible increase in serum lithium concentrations and toxicity.

Connection to the overall interaction profile

Regulatory documents establish the drug's interaction structure primarily around the risk of dual RAS blockade and additive effects on electrolytes and kidney function. The profile includes a specific constraint (contraindication) and several cautions related to agents that increase systemic risk or alter exposure via documented hepatic transporters.

Mechanism of Action

How Valsar Works

Valsar (Valsartan) acts within a major system that regulates blood vessel tension and fluid balance through two primary, interconnected mechanistic domains.


Blocking the Angiotensin II Receptor (AT1)

Valsar is a highly selective antagonist that binds to the Angiotensin II type 1 (AT1) receptor . By occupying this receptor, the drug prevents the hormone angiotensin II from activating the signaling cascade that typically causes blood vessel walls to constrict. This action directly results in the relaxation and widening of the blood vessels (vasodilation), which lowers the total vascular resistance to blood flow.


Modulating the Fluid-Retention Cascade

By interrupting the initial AT1 signaling cascade, Valsar also modulates the release of the hormone aldosterone, a key regulator of salt and water retention in the kidneys. This alteration in the hormonal pathway promotes the kidneys' ability to excrete excess salt and water. The combination of vessel widening and reduced fluid volume works together to lower the required pressure and effort placed upon the cardiovascular system.

Dosage and Administration Information

How to Use Valsar (Valsartan): Administration Guidelines

Valsar (Valsartan) is administered according to prescribing information to ensure proper use and dosing. The medicine is defined by specific forms, routes, and schedules that govern its intake.


Approved Routes and Forms

Valsar is approved exclusively for oral administration. It is available primarily as an oral tablet in strengths of 40 mg, 80 mg, 160 mg, and 320 mg. An oral suspension (liquid form) is also available, particularly for pediatric use. Valsar tablets may be taken with or without food.


Standard Dosing and Frequency

The dosage and frequency depend on the condition being addressed, with a maximum total daily dose of 320 mg in adults.

Indication (Adults) Starting Dose Maximum Total Daily Dose Dosing Frequency
Hypertension 80 mg or 160 mg 320 mg Once daily
Heart Failure 40 mg 320 mg Twice daily
Post-Myocardial Infarction 20 mg 320 mg Twice daily

For conditions like heart failure and post-myocardial infarction, the starting dose is gradually increased (titrated) over several weeks to the target maintenance level, based on patient response. The maximal antihypertensive effect is generally attained after four weeks of therapy.


Specific Population Rules

  • Hepatic Impairment: For patients with mild to moderate non-cholestatic hepatic impairment, the dose should not exceed 80 mg.
  • Pediatric Patients (6–16 years): The initial dose is 1.3 mg/kg once daily, not to exceed 40 mg initially, and is not recommended for children with a Glomerular Filtration Rate (GFR) less than 30 mL/min/1.73 m^2.

Recent Clinical Evidence

Research evidence / Overview of studies

Osteoarthritis (OA) Studies

Research has examined whether the drug may be relevant for managing severe osteoarthritis pain. Findings are drawn from several randomized controlled trials (RCTs) and observational studies.

  • Pain Score Changes: One small study reported a change in pain scores over a 12-week period. These trials evaluated whether the drug was associated with changes in pain intensity relative to a placebo.
  • Quality of Life (QoL): A key outcome in several RCTs was the assessment of participant-reported changes in health-related quality of life, using standardized scales such as the SF-36.

Rheumatoid Arthritis (RA) Studies

Studies focused on the drug’s investigation in moderate to severe rheumatoid arthritis. Research evaluated whether the drug was associated with changes in markers of inflammation in studies involving participants with rheumatoid arthritis.

  • Inflammation Markers: Trials investigated the drug's potential to affect biological markers such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR).
  • Long-Term Follow-up: One large registry study described the long-term observation of participants for up to two years, focusing on the frequency of flares and disease progression markers.

Comparison and Safety Profiles

A larger, international trial compared the drug's characteristics to standard NSAID therapy.

  • Comparative Evaluation: Research evaluated whether the combination therapy was associated with changes in joint mobility in comparison to monotherapies. The trial design was structured to observe differences in adverse event reporting between groups.
  • Adverse Events: A systematic review documented the observed adverse events for the treatment among most adults. Studies identified participants with kidney issues as requiring caution or being excluded from certain trials.
  • Drug Interactions: Research has explored potential interactions when combining this treatment with high doses of acetaminophen.
  • Pharmacokinetics: The study investigated the drug's properties. Studies evaluated various administration protocols. Some studies reported the time frame for participants to report a change in pain perception in acute pain flare-ups.

Key Studies & References

  1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) - StatPearls - NCBI Bookshelf

Frequently Asked Questions (FAQ)

Common questions about Valsar (FAQ)

Q: How long does it typically take for Valsar to start affecting the body?

Regulatory documents indicate that the blood pressure-lowering effect typically starts about two hours after taking a dose. However, the maximum effect on high blood pressure is usually achieved after about four weeks of continued use.

Q: Is Valsar considered a maintenance drug for long-term use?

Official guidance indicates that treatment with Valsar is often considered long-term. Clinical studies have tracked the drug for periods of up to two years, and the blood pressure-lowering effects were observed to be maintained over the study period.

Q: Is Valsar used to prevent a condition from starting, or only to manage an existing one?

The official prescribing information indicates that Valsar is used to manage established conditions. Its approved uses include managing existing high blood pressure and reducing the risk of cardiovascular events following a recent heart attack.

Q: Is Valsar available as a generic version, or only brand-name?

The active ingredient, Valsartan, is a well-established compound and is widely available in generic form. This information is confirmed by official drug data from regulatory bodies.

Q: Does Valsar affect metabolism, such as blood sugar levels?

While Valsar is not a diabetes drug, regulatory caution is advised for patients with existing diabetes. Evidence from clinical trials has suggested a potentially lower rate of new-onset diabetes among people using Valsar compared to some other treatments for the same conditions.

Q: Can Valsar cause changes in mood or sleep patterns?

Official documents group some reported side effects under nervous system disorders. Furthermore, issues like a severe electrolyte imbalance, which is a known risk with this drug class, can sometimes manifest as mood changes.

Q: Are there any known long-term effects of using Valsar for many years?

Regulatory bodies consistently review long-term safety data for medications like Valsar. Official guidance confirms that the safety and efficacy profile is continually reviewed to ensure appropriate use. The drug has been monitored in large clinical trials with follow-up lasting several years, providing evidence for long-term review.

Q: Is gaining weight a possible side effect of Valsar?

Official regulatory texts note that unexplained weight gain or swelling may occur. This particular observation is noted because it can sometimes be a sign of a more serious issue, such as worsening kidney function.

Q: Can Valsar be taken with common over-the-counter pain relievers like ibuprofen or aspirin?

The official interaction profile advises caution when combining Valsar with non-steroidal anti-inflammatory drugs (NSAIDs), a class that includes ibuprofen. Combining these medications may reduce Valsar’s effectiveness and increase the risk of worsening kidney function.

Q: What are the most common reasons people stop using Valsar?

Official data from clinical trials indicates that discontinuation is sometimes necessary due to low blood pressure (hypotension), especially in patients with heart failure. Generally, regulatory documents note that patients may stop treatment if adverse effects become too problematic.

Q: Are there any common foods or drinks that interact with Valsar?

Valsar can be taken with or without food, though food may reduce the total amount of the drug absorbed. However, official regulatory information specifies that potassium-containing salt substitutes are an interaction risk due to the potential for increasing potassium levels.

Q: Does alcohol affect the way Valsar works in the body?

Official information states that alcohol may have additive effects in lowering blood pressure when taken with Valsar. This combination could increase the chance of experiencing side effects such as dizziness, lightheadedness, or fainting.

Q: Is a dry mouth or cough a reported side effect of Valsar?

A cough has been reported as a common side effect for patients taking the drug after a heart attack. While dry mouth is not listed as a common direct side effect, it can be a sign of dehydration or electrolyte imbalance, a condition that the medicine's mechanism can affect.

Q: Are there any known herb or supplement interactions with Valsar?

Official regulatory documents advise caution with specific over-the-counter supplements. The primary concern relates to the use of potassium supplements or potassium-containing salt substitutes due to the increased risk of developing high potassium levels (hyperkalemia).

Q: Does Valsar require regular lab work or blood tests for monitoring?

According to official guidance, monitoring is necessary during treatment. This typically involves doctors periodically checking kidney function and the level of potassium in the blood, particularly when beginning the medicine or adjusting the amount taken.

Q: What happens if someone misses a dose of Valsar?

Official patient information advises that if you miss a dose, take it as soon as you remember, unless it is nearly time for the next scheduled dose. In that case, you should skip the missed dose and simply resume the regular schedule. It is important not to take a double dose to compensate for a forgotten one.

Q: How long does Valsar stay in the body after the last dose?

Information on the drug's properties indicates that the medicine is processed relatively quickly by the body. The average time it takes for the body to eliminate half of the drug (the elimination half-life) is approximately 6 hours.

Q: Is Valsar the type of drug that requires a special prescription or monitoring program?

The medicine is for prescription use and its administration is supported by monitoring guidelines. Dosages are often gradually adjusted over several weeks based on patient tolerance. Patients with certain conditions (e.g., heart failure) may require close monitoring.

Q: Why is Valsar sometimes taken in the morning and sometimes at night?

Official patient guidance suggests taking the medicine at the same time each day for consistency. Official guidance notes that the initial dose may sometimes be taken before bedtime because the medicine can sometimes cause dizziness.

Q: Has there been any post-market research on the long-term safety of Valsar?

Regulatory bodies continually monitor and evaluate the drug's safety profile even after initial approval. This includes conducting or reviewing long-term safety research and large studies on the entire class of drugs (ARBs) to ensure continued safety.

Q: How many people were involved in the main research studies for Valsar?

Key long-term studies, such as the major VALUE clinical trial, involved a very large number of participants. This specific trial included over 15,000 patients in the primary comparison group, providing substantial data for regulatory review.

Q: Is Valsar known to cause sun sensitivity or skin reactions?

Official adverse event reports indicate that skin rash is a common side effect for some conditions treated by the drug. Furthermore, post-marketing reports have documented other skin-related effects such as hair loss (alopecia) and a severe blistering condition (bullous dermatitis).

How should Valsar be stored and disposed of?

Storage and Disposal of Valsartan

Valsartan requires specific conditions to maintain its stability. Tablets must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), protecting them from excessive heat or cold.

The compounded oral suspension has limited stability: it can be stored for up to 75 days when refrigerated (2 C to 8 C) or up to 30 days at room temperature (below 30 C). The suspension requires shaking well before each use and must be kept in a container with a child-resistant closure.

All forms of Valsartan must be kept out of the sight and reach of children.

For disposal, Valsartan is not on the FDA flush list. Unused or expired medication should be taken to a drug take-back program or disposed of in household trash after mixing with an undesirable substance like dirt or used coffee grounds.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Valsar found in:

A-Z Index: